Lebanon: A recent study analyzing data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) has ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

Being overweight raises your risk of thyroid cancer ... One study reported that the incidence of thyroid cancer in semaglutide-treated patients was less than 1%. As of now, the FDA warning ...

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

Ozempic and similar semaglutide-based medications have been hailed as miracle drugs. Known as GLP-1 (glucagon-like peptide-1) ...

However, semaglutide was not linked to a significantly reduced risk of developing thyroid, stomach, or breast cancer. Yoni Resnick, PharmD, the director of pharmacy clinical services with New ...

Weight loss drug Wegovy uses the same drug as Ozempic, called semaglutide, and has been licensed for use in the UK. Wegovy ...

The following text highlights some of these precautions. Boxed warning: Risk of thyroid cancer Semaglutide (the active ingredient in Ozempic and Wegovy) has a boxed warning for a possible risk of ...

Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...

Commonly prescribed GLP1-RAs include Ozempic (semaglutide), Victoza (liraglutide), and Trulicity ... including the U.S. Food and Drug Administration (FDA), to require thyroid cancer risk warnings on ...

Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk ... semaglutide injection 2.4 mg contains a Boxed Warning for possible thyroid tumors, including cancer ...